These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 14640934

  • 1. Recurrent hope for the treatment of preterm delivery.
    Doggrell SA.
    Expert Opin Pharmacother; 2003 Dec; 4(12):2363-6. PubMed ID: 14640934
    [Abstract] [Full Text] [Related]

  • 2. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
    Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    N Engl J Med; 2003 Jun 12; 348(24):2379-85. PubMed ID: 12802023
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
    Facchinetti F, Vaccaro V.
    Minerva Ginecol; 2009 Oct 12; 61(5):401-9. PubMed ID: 19749671
    [Abstract] [Full Text] [Related]

  • 4. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
    Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, Perrotin F, Bohec C, Connan L, Vayssière C, Langer B, Mantel A, Azimi S, Porcher R, Azria E, Groupe De Recherche En Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2012 Mar 12; 206(3):206.e1-9. PubMed ID: 22381603
    [Abstract] [Full Text] [Related]

  • 5. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K, Childress K, Vricella LK, Boerrigter A, Franklin BHK, Sauer M, Armbruster R, Tomlinson T.
    Am J Obstet Gynecol MFM; 2020 Nov 12; 2(4):100219. PubMed ID: 33345927
    [Abstract] [Full Text] [Related]

  • 6. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
    Stetson B, Hibbard JU, Wilkins I, Leftwich H.
    Obstet Gynecol; 2016 Nov 12; 128(5):983-988. PubMed ID: 27741201
    [Abstract] [Full Text] [Related]

  • 7. 17 hydroxyprogesterone for the prevention of preterm delivery.
    Meis PJ, Society for Maternal-Fetal Medicine.
    Obstet Gynecol; 2005 May 12; 105(5 Pt 1):1128-35. PubMed ID: 15863556
    [Abstract] [Full Text] [Related]

  • 8. Does progesterone treatment influence risk factors for recurrent preterm delivery?
    Meis PJ, Klebanoff M, Dombrowski MP, Sibai BM, Leindecker S, Moawad AH, Northen A, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S.
    Obstet Gynecol; 2005 Sep 12; 106(3):557-61. PubMed ID: 16135587
    [Abstract] [Full Text] [Related]

  • 9. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar 12; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 10. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S, Roman AS.
    Womens Health (Lond); 2012 Jan 12; 8(1):21-30. PubMed ID: 22171770
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
    Saghafi N, Khadem N, Mohajeri T, Shakeri MT.
    J Obstet Gynaecol Res; 2011 Oct 12; 37(10):1342-5. PubMed ID: 21564406
    [Abstract] [Full Text] [Related]

  • 12. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K.
    Obstet Gynecol; 2005 Feb 12; 105(2):267-72. PubMed ID: 15684150
    [Abstract] [Full Text] [Related]

  • 13. ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
    American College of Obstetricians and Gynecologists.
    Obstet Gynecol; 2003 Nov 12; 102(5 Pt 1):1115-6. PubMed ID: 14672496
    [Abstract] [Full Text] [Related]

  • 14. The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
    Rebarber A, Cleary-Goldman J, Istwan NB, Rhea DJ, Desch C, Russo-Stieglitz K, Saltzman DH.
    Am J Perinatol; 2008 May 12; 25(5):271-5. PubMed ID: 18401840
    [Abstract] [Full Text] [Related]

  • 15. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, Connan L, Vayssière C, Langer B, Capelle M, Azimi S, Porcher R, Rozenberg P, Groupe de Recherche en Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2015 Apr 12; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [Abstract] [Full Text] [Related]

  • 16. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Singh J, Istwan N, Rhea D, Driggers RW.
    Am J Perinatol; 2014 Jan 12; 31(1):55-60. PubMed ID: 23456908
    [Abstract] [Full Text] [Related]

  • 17. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G.
    Am J Perinatol; 2010 Apr 12; 27(4):343-8. PubMed ID: 20013580
    [Abstract] [Full Text] [Related]

  • 18. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
    Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, Varner M, Malone F, Iams JD, Mercer BM, Thorp J, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M, Anderson G, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
    N Engl J Med; 2007 Aug 02; 357(5):454-61. PubMed ID: 17671253
    [Abstract] [Full Text] [Related]

  • 19. Progestogen administration in pregnancy may prevent preterm delivery.
    Keirse MJ.
    Br J Obstet Gynaecol; 1990 Feb 02; 97(2):149-54. PubMed ID: 2138496
    [Abstract] [Full Text] [Related]

  • 20. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
    Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    Am J Obstet Gynecol; 2007 Mar 02; 196(3):224.e1-4. PubMed ID: 17346529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.